Arphio is an orphan pharmaceutical company founded on the mission to improve patient access to vital treatments for rare diseases.
We believe that collaboration always yields the best results. That is why we are driven by the conviction that it is only by combining our expertise and global market reach with leading specialists in the development of orphan products that can we make vital treatments of rare diseases available to a broader population worldwide.
There are now over 300 million people living with one or more of over 6,000 identified rare diseases around the world, each supported by family, friends, and caregivers. Currently a medication is only available for about 5% of all rare disease patients and their access to these treatments is often very problematic, due to regulatory and financial burdens.
The story behind Arphio is an interesting one. Two leading pharmaceutical companies partnering with the mission to improve access to vital treatments to patients suffering from rare diseases. When selecting the name and visual identity the mission a...
Aztiq and SK Pharma are thrilled to announce the recent establishment of a new entity ArphioTM, a powerhouse, solely dedicated to orphan drugs with the intention of improving access to vital treatments, to patients suffering from rare diseases and wi...